Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis
- 1 January 2006
- journal article
- clinical trial
- Published by Informa UK Limited in Amyloid
- Vol. 13 (4), 236-249
- https://doi.org/10.1080/13506120600960882
Abstract
Objective. Rate-limiting transthyretin (TTR) tetramer dissociation and monomer misfolding enable misassembly into numerous aggregate morphologies including amyloid, a process genetically linked to and thought to cause amyloid pathology. T119M TTR trans-suppressor subunit inclusion into tetramers otherwise composed of disease-associated subunits ameliorates human amyloidosis by increasing the tetramer dissociation barrier. Diflunisal binding to the 99% unoccupied L-thyroxine binding sites in TTR also increases the tetramer dissociation barrier; hence, we investigated the feasibility of using diflunisal for the treatment of human TTR amyloidosis using healthy volunteers. Methods. Diflunisal (125, 250 or 500 mg bid) was orally administered to groups of 10 subjects for 7 days to evaluate serum diflunisal concentration, diflunisal binding stoichiometry to TTR, and the extent of diflunisal imposed TTR kinetic stabilization against urea- and acid-mediated TTR denaturation in human serum. The rates of urea-mediated tetramer dissociation and acid-mediated aggregation as a function of diflunisal concentration were also evaluated in vitro, utilizing physiologically relevant concentrations identified by the above experiments. Results. In the 250 mg bid group, 12 h after the 13th oral dose, the diflunisal serum concentration of 146 ± 39 μM was sufficient to afford a TTR binding stoichiometry exceeding 0.95 ± 0.13 (≈1.75 corrected). Diflunisal binding to TTR at this dose slowed urea-mediated dissociation and acid-mediated TTR aggregation at least, threefold (p < 0.05) in serum and in vitro, consistent with kinetic stabilization of TTR. Conclusion. Diflunisal-mediated kinetic stabilization of TTR should ameliorate TTR amyloidoses, provided that the nonsteroidal anti-inflammatory drug liabilities can be managed clinically.Keywords
This publication has 59 references indexed in Scilit:
- Native State Kinetic Stabilization as a Strategy To Ameliorate Protein Misfolding Diseases: A Focus on the Transthyretin AmyloidosesAccounts of Chemical Research, 2005
- Kinetic Stabilization of the Native State by Protein Engineering: Implications for Inhibition of Transthyretin AmyloidogenesisJournal of Molecular Biology, 2005
- Diflunisal Analogues Stabilize the Native State of Transthyretin. Potent Inhibition of AmyloidogenesisJournal of Medicinal Chemistry, 2003
- Cardiac Amyloid in Patients with Familial Amyloid Polyneuropathy Consists of Abundant Wild-Type TransthyretinBiochemical and Biophysical Research Communications, 2000
- Electrically neutral microheterogeneity of human plasma transthyretin (prealbumin) detected by isoelectric focusing in urea gradientsElectrophoresis, 1999
- Revised transthyretin Ile 122 allele frequency in African-AmericansHuman Genetics, 1996
- Change in Variant Transthyretin Levels in Patients with Familial Amyloidotic Polyneuropathy Type I Following Liver TransplantationBiochemical and Biophysical Research Communications, 1995
- Pharmacokinetics of Diflunisal in PatientsClinical Pharmacokinetics, 1991
- Transthyretin microheterogeneity and thyroxine binding are influenced by non-amino acid components and glutathione constituentsBiochemical and Biophysical Research Communications, 1989
- The chemistry, pharmacology and clinical pharmacology of diflunisalCurrent Medical Research and Opinion, 1978